What is the preferred antibiotic and dosing for a urinary tract infection caused by multidrug‑resistant Acinetobacter in an adult with normal renal function?

Antibiotic of Choice for Multidrug-Resistant Acinetobacter in Urine Culture

For urinary tract infections caused by multidrug-resistant Acinetobacter baumannii in adults with normal renal function, high-dose sulbactam (ampicillin-sulbactam or cefoperazone-sulbactam) is the preferred first-line agent when the sulbactam MIC is ≤4 mg/L, administered as 9-12 g/day of sulbactam divided into 3 doses with 4-hour extended infusions. 1, 2

Treatment Algorithm Based on Susceptibility

First-Line: Sulbactam-Based Regimens (MIC ≤4 mg/L)

Ampicillin-sulbactam is the preferred sulbactam-containing agent for carbapenem-resistant Acinetobacter baumannii (CRAB) when susceptibility is documented. 2

• Dosing: 3 g IV every 6 hours (total 12 g/day) administered as 4-hour extended infusions 1, 3
• Alternative high-dose regimen: 9-12 g/day of sulbactam component divided into 3 doses (3-4 g every 8 hours) 1
• Duration: 7-14 days for complicated UTI 3

Cefoperazone-sulbactam is an alternative sulbactam-containing option, particularly in regions where it is available:

• Dosing: 3 g/3 g IV every 8 hours (providing 6-9 g sulbactam daily) 1
• Administration: 4-hour extended infusions optimize pharmacokinetic/pharmacodynamic properties 1

Rationale for Sulbactam Preference

Sulbactam has intrinsic activity against A. baumannii independent of its beta-lactamase inhibitor properties and demonstrates significantly superior safety compared to colistin. 2 Clinical outcomes with sulbactam for severe Acinetobacter infections are equivalent to imipenem, including for carbapenem-resistant isolates. 2 Most importantly, nephrotoxicity rates are markedly lower with sulbactam (15.3%) compared to colistin (33%), making it particularly advantageous for UTI treatment where renal excretion is critical. 2

Second-Line: Colistin (When Sulbactam MIC >4 mg/L or Resistance)

Colistin should be reserved for strains resistant to sulbactam to preserve its effectiveness and avoid unnecessary toxicity. 2

• Loading dose: 6-9 million IU IV 2
• Maintenance dose: 2.5-5 mg/kg/day divided into 2-4 doses for normal renal function 4
• Alternative dosing from FDA label: 2.5 to 5 mg/kg per day of colistin base in 2 to 4 divided doses 4
• Duration: 7-14 days 3

For UTI specifically, colistin achieves high urinary concentrations and has demonstrated efficacy in case series, though nephrotoxicity remains a significant concern. 5, 6

Third-Line: Polymyxin B (Sulbactam MIC ≥32 mg/L)

When the sulbactam MIC is ≥32 mg/L (eight-fold higher than the susceptibility threshold), ampicillin-sulbactam is ineffective even at high doses. 2

• Loading dose: 2-2.5 mg/kg IV 2
• Maintenance dose: 1.5-3 mg/kg/day divided into 2 doses or continuous infusion 2
• Monitoring: Close renal function surveillance is mandatory 2

Combination Therapy Considerations

There are no convincing data to recommend combination therapy over monotherapy for directed treatment of A. baumannii UTI when the organism is susceptible to the chosen agent. 2

However, combination therapy may be considered in specific scenarios:

• Clinical failure with monotherapy 2
• Isolates with MICs at the upper limit of susceptibility 2
• Documented polymyxin resistance: tigecycline-based regimen (200 mg loading, then 100 mg q12h) combined with high-dose meropenem or rifampicin 2

Avoid these combinations:

• Colistin plus rifampin (not recommended routinely) 2
• Colistin with anti-Gram-positive agents (increases nephrotoxicity) 2

Critical Pitfalls to Avoid

1. Underdosing sulbactam: Doses <9 g/day may be insufficient for severe multidrug-resistant infections 1

2. Empiric use without culture data: Always obtain urine culture before initiating therapy and adjust based on susceptibility results 3

3. Ignoring MIC values: Sulbactam is only effective when MIC ≤4 mg/L; using it for higher MICs leads to treatment failure 1, 2

4. Premature colistin use: Reserve colistin for sulbactam-resistant strains to minimize nephrotoxicity and preserve effectiveness 2

5. Inadequate infusion time: Standard bolus dosing of sulbactam is inferior to 4-hour extended infusions for optimizing drug exposure 1

6. Insufficient treatment duration: Completing <7 days for complicated UTI increases relapse risk 3

Alternative Agents for Carbapenem-Resistant Enterobacteriaceae (Not Acinetobacter)

The guideline evidence provided focuses on CRE (carbapenem-resistant Enterobacteriaceae) rather than Acinetobacter for several newer agents. These are not recommended for Acinetobacter but are mentioned for completeness:

• Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam are active against CRE but not against CRAB 7, 8, 9
• Plazomicin and aminoglycosides may have variable activity but lack robust evidence for Acinetobacter UTI 7

Monitoring Parameters

• Obtain urine culture before treatment initiation 3
• Assess clinical improvement within 48-72 hours 3
• Monitor renal function closely, especially with colistin or polymyxin B 2, 4
• Continue treatment for minimum 48-72 hours beyond symptom resolution 3